Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
12don MSN
Early HIV drugs give immune system a brief reprieve before dysregulation returns, study finds
Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term.
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...
Lenacapavir is an injectable medicine that only needs to be taken twice a year, making it easier to use than daily HIV pills.
Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...
Funding for HIV care and prevention are key for continued progress, but recent cuts to federal funding for health agencies, ...
News Medical on MSN
Medicaid Expansion Increases Access to HIV Prevention Medication for High-Risk Populations
Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...
Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...
Organizations that provide services like HIV education and living recommendations are being forced to cut programming after ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback